Synthekine
- Founded: 2018
- Location: Menlo Park, CA
- Employee range: 50 - 200
- Clinical stage: Clin1
- Therapy area: Immuno-oncology
- Drug types: ONC, IMM
- Lead product: STK-012
- Product link: https://www.synthekine.com/our-pipeline/
- Funding: $100M C Jan 2023; $107.5M B Jun 2021; $82M A Sep 2020
- Investors: The Column Group
synthekine.com linkedin.com job board
Short description:
Engineered Cytokines
Drug notes:
STK-009 2 efforts Clin0/Clin1oncology; undisclosed Clin0 immuno-oncology; 2 undisclosed programs RD/Clin0 autoimmune conditions
Long description:
Contact us to add description: recruit@workinbiotech.com
© 2024 Work In Biotech LLC
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com